2013년 5월 21일 23:00

Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today presented positive safety and efficacy results from its large multicenter trial of plecanatide in patients w...

2013년 5월 15일 09:52

Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq:^NBI), effective prior to the...

2013년 5월 10일 09:43

Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the first quarter ended March 31, 2013. Synergy is developing pleca...

2013년 4월 17일 09:48

Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock

Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its underwritten public offering of 16,375,000 shares of common stock at an offering price of $5.50 per ...

2013년 4월 11일 10:05

Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing of an underwritten public offering of 16,375,000 shares of its common stock. The gross proceeds to S...

2013년 4월 10일 09:54

Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it is offering to sell an aggregate value of $90,000,000 of its common stock in an underwritten public offe...

2013년 2월 11일 19:00

Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its common stock has been approved for listing on The NASDAQ Global Market under the symbol “SGYP.” Trading...

2013년 1월 28일 19:00

Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis

Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders, announced today that oral dosing of healthy volunteers has begun in a Phase I clinical trial of SP-333, a guanylate cyclase C (GC-C) ag...

2013년 1월 18일 08:23

Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its previously announced merger with Callisto Pharmaceuticals, Inc. (formerly OTC QB: CLSP) closed effectiv...

2013년 1월 15일 19:00

Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (“Synergy”) today announced that it convened its annual meeting of stockholders yesterday and it has received the necessary approvals from its stockholders to authorize Synergy's merger with Callisto Phar...

2013년 1월 2일 19:00

Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation

Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide, its investigational oral drug for the treatment of chronic idiopathic constipation (CIC), was well tolerated and met the primary and key secondary endpoints of a Phase I...

2012년 12월 28일 19:00

Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the successful completion of a Phase I single-ascending-dose clinical trial of SP-333, a guanylate cyclase ...